Bone Biologics Co. (NASDAQ:BBLG) Sees Large Increase in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 72,100 shares, an increase of 48.4% from the October 15th total of 48,600 shares. Based on an average daily volume of 3,010,000 shares, the short-interest ratio is currently 0.0 days. Approximately 13.8% of the company’s stock are short sold.

Bone Biologics Stock Down 7.8 %

Bone Biologics stock opened at $1.19 on Friday. The firm’s fifty day moving average price is $1.64 and its 200 day moving average price is $1.59. Bone Biologics has a 12-month low of $0.80 and a 12-month high of $10.56.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.